Page last updated: 2024-08-26

bosentan anhydrous and Left Ventricular Dysfunction

bosentan anhydrous has been researched along with Left Ventricular Dysfunction in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (12.50)18.2507
2000's6 (75.00)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Argyropoulou, P; Boutou, AK; Pitsiou, G; Stanopoulos, I1
Galiè, N; Guazzi, M1
Brauchlin, AE; Nicod, LP; Rochat, T; Soccal, PM; Spiliopoulos, A; Trindade, PT1
Caspi, A; Cotter, G; Kaluski, E; Kobrin, I; Krakover, R; Leitman, M; Milo-Cotter, O; Moriconi, T; Rainisio, M; Reizin, L; Vered, Z; Zimlichman, R1
Barbe, F; Carayon, A; Choussat, R; Crozatier, B; Hittinger, L; Maistre, G; Su, J1
Goldstein, S; Mishima, T; Sabbah, HN; Sharov, VG; Suzuki, G; Tanimura, M; Todor, A1
Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG1
Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM1

Reviews

1 review(s) available for bosentan anhydrous and Left Ventricular Dysfunction

ArticleYear
Pulmonary hypertension in left heart disease.
    European respiratory review : an official journal of the European Respiratory Society, 2012, Dec-01, Volume: 21, Issue:126

    Topics: Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Electrocardiography; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Exercise Test; Heart Valve Prosthesis; Humans; Hypertension, Pulmonary; Mitral Valve; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Wedge Pressure; Radiography, Thoracic; Stroke Volume; Sulfonamides; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Left; Weight Loss

2012

Trials

1 trial(s) available for bosentan anhydrous and Left Ventricular Dysfunction

ArticleYear
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
    Cardiology, 2008, Volume: 109, Issue:4

    Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Hypertension, Pulmonary; Male; Severity of Illness Index; Sulfonamides; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left

2008

Other Studies

6 other study(ies) available for bosentan anhydrous and Left Ventricular Dysfunction

ArticleYear
Pulmonary hypertension therapy and COPD: still many questions to be answered.
    The European respiratory journal, 2009, Volume: 33, Issue:2

    Topics: Bosentan; Exercise; Humans; Hypertension, Pulmonary; Perfusion; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Left

2009
Severe left ventricular dysfunction secondary to primary pulmonary hypertension: bridging therapy with bosentan before lung transplantation.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2005, Volume: 24, Issue:6

    Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Severity of Illness Index; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right

2005
Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
    Cardiovascular research, 1998, Volume: 39, Issue:3

    Topics: Animals; Bosentan; Cardiac Output; Cardiac Pacing, Artificial; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Heart Failure; Hemodynamics; Male; Protein Precursors; Stroke Volume; Sulfonamides; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Pressure

1998
Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Journal of the American College of Cardiology, 2000, Volume: 35, Issue:1

    Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Dogs; Heart Failure; Infusions, Intravenous; Myocardium; Stroke Volume; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2000
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
    Circulation, 2000, Sep-19, Volume: 102, Issue:12

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left

2000
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
    Journal of molecular and cellular cardiology, 2001, Volume: 33, Issue:5

    Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left

2001